论文部分内容阅读
目的探讨孟鲁司特治疗病毒感染婴幼儿喘息患者的辅助治疗效果,以期能够减轻婴幼儿喘息患者的痛楚。方法收集2013年10月至2014年10月于天门市妇幼保健院收治的病毒感染婴幼儿喘息患者60例,随机分为观察组(30例)和对照组(30例)。对照组常规治疗,观察组在常规治疗的基础上加用孟鲁司特治疗,观察两组婴幼儿喘息患者的临床治疗效果。结果观察组患者的总有效率为93.3%,高于对照组的80.0%,差异有统计学意义(P<0.05)。观察组婴幼儿喘息患者的咳嗽以及啰音消失时间较对照组时间更短,吸氧、雾化以及激素的使用情况更少,差异均有统计学意义(P<0.05)。两组患者在接受治疗后HCO_3、PaCO_3、PaO_2等值均明显升高,与治疗前比较差异有统计学意义(P<0.05)。结论孟鲁司特治疗病毒感染婴幼儿喘息患者中的辅助治疗效果比较理想,副作用比较小,具有重要的临床研究价值。
Objective To explore the effect of adjuvant treatment of montelukast in the treatment of wheezing infants with virus infection in order to reduce the pain of wheezing in infants and young children. Methods Sixty patients with wheezing and infantile asthma admitted to Tianmen MCH from October 2013 to October 2014 were randomly divided into observation group (30 cases) and control group (30 cases). The control group, conventional treatment, the observation group on the basis of conventional therapy plus montelukast treatment, observation of two groups of infants and young children wheezing clinical treatment effect. Results The total effective rate of the observation group was 93.3%, which was higher than that of the control group (80.0%), the difference was statistically significant (P <0.05). The observation group had shorter cough and rales disappearance time of asthmatic children than control group, less oxygen inhalation, atomization and less hormone use, the difference was statistically significant (P <0.05). After treatment, HCO_3, PaCO_3, PaO_2 and other values were significantly increased in both groups, with statistical significance (P <0.05). Conclusion The adjuvant therapy of montelukast in the treatment of infantile asthma patients with viral infection is quite satisfactory and the side effects are relatively small, which has important clinical research value.